Commave Theranostics

Commave Theranostics is a private biotechnology company founded in 2023 by Dr. David Hung, a prominent biotech entrepreneur known for founding Medivation and currently serving as the CEO of Nuvation Bio. The company is focused on the development of next-generation oncology treatments, specifically leveraging theranostic approaches and targeted radiopharmaceuticals. Headquartered in New York City, Commave Theranostics operates in a relatively stealthy manner, with its research programs primarily in the pre-clinical stage. The company aims to integrate diagnostic imaging with targeted therapy to improve outcomes for patients with various solid tumors. By utilizing the deep oncology expertise of its leadership, Commave Theranostics seeks to advance the field of precision medicine through highly targeted radiation delivery.